Industry still waiting for details of common technical specifications under IVD (in vitro diagnostic) Directive
This article was originally published in Clinica
Industry in Europe is still none the wiser as to exactly which in vitro diagnostic (IVD) products perceived as having a high degree of potential risk will be subject to specific technical requirements or controls - the so-called common technical specifications (CTSs) - under the new IVD Directive when it takes effect next year. There has been progress on the matter, however.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.